Unknown

Dataset Information

0

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

ABSTRACT:

SUBMITTER: Brockelmann PJ 

PROVIDER: S-EPMC11976262 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

Bröckelmann P J PJ   Müller H H   Fuchs M M   Gillessen S S   Eichenauer D A DA   Borchmann S S   Robertz A S AS   Behringer K K   Welters J J   Ferdinandus J J   Böll B B   Tharmaseelan H H   Yang X X   Kobe C C   Eich H -T H-   Baues C C   Klapper W W   Borchmann P P   von Tresckow B B  

Leukemia 20250324 4

Similar Datasets

Unknown Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.
| S-EPMC11925506 | biostudies-literature
Unknown Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
| S-EPMC8885415 | biostudies-literature
Unknown Relapsed Hodgkin lymphoma: management strategies.
| S-EPMC4909353 | biostudies-literature
Unknown Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.
| S-EPMC6346242 | biostudies-literature
Unknown Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
| S-EPMC10776396 | biostudies-literature
Unknown Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.
| S-EPMC8297052 | biostudies-literature
Unknown Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.
| S-EPMC10651466 | biostudies-literature
Unknown Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
| S-EPMC7193521 | biostudies-literature
Unknown Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
| S-EPMC7601361 | biostudies-literature
Unknown Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
| S-EPMC9198905 | biostudies-literature